Jefferies Reiterates Buy Rating on Amarin Corporation (AMRN)

Jefferies analyst Michael Yee reiterated a Buy rating and $30.00 price target on Amarin Corporation (NASDAQ: AMRN).

The analyst comments "AHA issued an updated science advisory report for use of omega-3 fatty acids (fish oils) for management of hypertriglyceridemia. Although this is not a formal guideline update, we note AHA has historically been slow to update guidelines (took long time for PCSK9). Scripts continue to grow every week despite no label change and we think 2020 numbers are too low; we are positive but fully acknowledge investors remain nervous into a panel presumably in Nov."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $15.66 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Jefferies Upgrades Brightstar Lottery (BRSL) to Buy